ADAP
Adaptimmune Therapeutics
ADAP
ADAP
Delisted
ADAP was delisted on the 27th of October, 2025.
65 hedge funds and large institutions have $27.7M invested in Adaptimmune Therapeutics in 2025 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 10 increasing their positions, 18 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
more ownership
Funds ownership: →
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
3% less funds holding
Funds holding: 67 → 65 (-2)
44% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 18
Holders
65
Holding in Top 10
1
Calls
$11K
Puts
–
Top Buyers
| 1 | +$547K | |
| 2 | +$405K | |
| 3 | +$214K | |
| 4 |
AC
Almitas Capital
Santa Monica,
California
|
+$29.1K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$21.4K |
Top Sellers
| 1 | -$344K | |
| 2 | -$253K | |
| 3 | -$229K | |
| 4 |
MAM
MPM Asset Management
Boston,
Massachusetts
|
-$140K |
| 5 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$129K |